Ignite Creation Date:
2024-05-06 @ 3:53 PM
Last Modification Date:
2024-10-26 @ 1:59 PM
Study NCT ID:
NCT04797793
Status:
COMPLETED
Last Update Posted:
2021-04-01
First Post:
2021-03-12
Brief Title:
A Study Comparing Adapalene Gel 01 and to Differin Gel in the Treatment of Acne Vulgaris
Sponsor:
Taro Pharmaceuticals USA
Organization:
Taro Pharmaceuticals USA
Study Overview
Official Title:
A Double-blind Randomized Placebo Controlled Study to Compare Adapalene Gel 01 to Differin Gel and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris
Status:
COMPLETED
Status Verified Date:
2021-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To demonstrate therapeutic equivalence and safety of adapalene gel 01 Taro Pharmaceuticals USA Inc and Differin Gel Adapalene Gel 01 Galderma in the treatment of acne vulgaris
Detailed Description:
A multi-center double-blind randomized placebo controlled parallel-group study Adapalene Gel 01 Taro Pharmaceuticals USA Inc and to Differin Gel Adapalene 01 Galderma and both active treatments to a placebo control in the treatment of acne vulgaris
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None